4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.
Cell & Gene: The Podcast
00:00
Strategic Investments and Partnerships in Biotech
Exploring how Estellis' strategic investment in Poseita has accelerated their progress in clinical data, including board observer seats and priority on their solid tumor program, as well as the advantages of partnering with Novartis, Takeda, and Roche.
Transcript
Play full episode
